A new antibody drug by pharmaceutical company inflaRx received FDA emergency use authorization to treat critically ill Covid-19 patients. One of the greatest hurdles for monoclonal antibody development during the Covid-19 pandemic is the ongoing mutation of the SARS-CoV-2 virus. Most antibodies introduced throughout the pandemic targeted the virus spike protein, which mutates significantly with every emerging
COVID is not yet under control. Despite a bevy of vaccines, monoclonal antibodies, and antivirals, the virus continues to mutate and elude us. One solution that scientists have been exploring since the early days of the pandemic may come in the form of tiny antibodies derived from llamas, which target various parts of the SARS-CoV-2 spike protein.
Hearts from mice infected with COVID-19 have an increased percentage of fibrosis and dilation of the fibers—a common indicator of early cardiomyopathy in mice. Image courtesy of Andrew Marks. Scientists find that COVID-19 infection can cause changes in calcium channels that can affect how the heart beats, it can also trigger inflammation and oxidative stress
A team led by McMaster University researchers Gilmar Reis and Edward Mills has discovered that a single injection of pegylated interferon lambda can successfully treat COVID-19 in people early in the disease. A team led by McMaster University researchers Gilmar Reis and Edward Mills has discovered that a single injection of pegylated interferon lambda (lambda)
By addressing molecules governing how host cells respond to the SARS-CoV-2 virus, researchers hope they’ve found a new therapeutic target less vulnerable to potential drug resistance and emerging variants of concern Researchers at University of California San Diego and UC Riverside have further elucidated the molecular pathway used by the SARS-CoV-2 virus to infect human
Over the past three years, it has become clear that, for many people, the effects of SARS-CoV-2 infection persist long after an initial case of COVID-19 wanes. Like primary COVID-19, the affliction, known as post-acute sequelae of SARS-CoV-2 (PASC) or long COVID, has highly variable duration, symptoms and severity. And as data accumulates, it appears
A new report has highlighted the consequences of misinformation, including loss of trust in public institutions, delayed action on pressing issues such as climate change, and the financial toll on healthcare services during the COVID-19 pandemic. The ‘Fault Lines’ report involved a panel of international experts, including leading cognitive scientist Professor Stephan Lewandowsky, from the University of
People hospitalized with COVID-19 may have an increased risk for heart damage, but not so much the type of inflammation previous research suggested, according to a new study. Early in the pandemic, several studies suggested many COVID-19 survivors experienced heart damage even if they didn’t have underlying heart disease and weren’t sick enough to be hospitalized. The
A booster (third) dose of a SARS-CoV-2 vaccine was associated with a 90% reduction in death in people with multiple health conditions compared to 2 doses, according to a new study from Hong Kong published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.221068. “We found a substantially reduced risk of COVID-19–related death in adults with multimorbidity who received a
COVID-19 is associated with higher risks of cardiovascular disease and death in the short- and long-term, according to a study in nearly 160,000 participants published today in Cardiovascular Research, a journal of the European Society of Cardiology (ESC). Compared to uninfected individuals, the likelihood of COVID-19 patients dying was up to 81 times higher in
